SIGNATOPE develops the next generation of protein biomarker assays using a special type of immunoaffinity based mass spectrometry assays.
Business Model:
Revenue: $0
Employees: 11-50
Address:
City: Reutlingen
State: Baden-Wurttemberg
Zip:
Country: Germany
It develops the next generation of protein biomarker assays using a novel type of mass spectrometry-based immunoassays. SIGNATONE immunoassays are capable of detecting and quantifying protein biomarkers in humans and all pharmacologically relevant model species. Antibodies comprising epitopes of 4 amino acids are the key reagents of SIGNATOPE´s immunoassays.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 5/2017 | Seed Round | 1 | $671k |
High-Tech Grunderfonds High-Tech Grunderfonds |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|